Therapeutics

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Harnessing the modified proteome for increased diagnostic power

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased… Read More

#Archive

#Academic #Analysis #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Precision medicine #Regulatory #RNA #Sequencing #Stem cells #System biology #Therapeutics

Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics

Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These vesicles can… Read More

#Archive #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

2030 Life Sciences and Health in the Digital Age (Part 2)

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Oncology #Regulatory #Screening #Sequencing #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal... driving stronger biomarker-based insights and… Read More

#Archive

Bacteriophage
#AI / data analytics / healthtech / informatics #Animal models #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Oncology #Preclinical #Stem cells #System biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Bitten by the Bug – A flurry of investments fuel microbiome drug discovery

By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To capitalise on the microbiome’s potential to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microbiome #Oncology #Pharmokinetics #Preclinical #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Microbiology #Nanomedicine / nanotechnology #Organic chemistry #Pathology #Precision medicine #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

2030 Life Sciences and Health in the Digital Age (Part 1)

2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look ahead, to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Automating Automation – How close are we to Artificial Intelligence impact?

Automating Automation - How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Precision medicine #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Application of bioinformatics in support of precision medicine

Application of bioinformatics in support of precision medicine By Mike Furness and John Wise Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. With the support of new technologies and tools, bioinformatics can play an important… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene editing #Gene therapy #Genomics #Lead discovery #Oncology #Pharmacology #Regenerative Medicine #Regulatory #Screening #Stem cells #System biology #Systems biology #Therapeutics

Cell Therapy – Falling short of its potential?

Cell Therapy - Falling short of its potential? By Pierre-Louis Joffrin Despite major investment in the field, few cell therapies have gained regulatory approval with limited commercial success. The success of therapeutic products is defined by three factors: safety, efficacy and scalability. Achieving these for cell therapy presents new challenges;… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biomarkers #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #Screening #Sequencing #Stem cells #System biology #Therapeutics #Toxicology

How Mergers and Acquisitions Will Drive Oncology Research in 2019

How Mergers and Acquisitions Will Drive Oncology Research in 2019 By Dr Michael Seiler 2019 got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession. These ventures provide a window into key trends in oncology research, where investigators are likely… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

From Genotype to Phenotype: Leveraging functional genomics in oncology

From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine. In 2011, AstraZeneca initiated a strategic ‘5R Framework’… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genomics #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Integrated Platform Drug Discovery and Development Companies – Part 2: Comparative analysis

Integrated Platform Drug Discovery and Development Companies - Part 2: Comparative analysis By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr Spring 2019 Large pharmaceutical companies have struggled to efficiently implement tools, technologies and platforms into their drug discovery and development (DDD) programmes. More recently there have been attempts… Read More

#Archive

Organoids
#Academic #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pathology #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

The Growth of Organoids in Cancer Drug Discovery

The Growth of Organoids in Cancer Drug Discovery By Dr J. Mark Treherne, et al., Will the automated expansion of organoids help improve the productivity of cancer drug discovery? Increasingly, complex cell-based assays and tissues are routinely used as part of cancer drug discovery. However, conventional monolayer or suspension cultures… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High throughput screening #Imaging #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Organic chemistry #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

Increasing Drug Discovery Success With 3D Cell Culture Systems

Increasing Drug Discovery Success With 3D Cell Culture Systems By Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when… Read More

#Archive

#Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Microfluidics #Precision medicine #Screening #Sequencing #Target validation #Therapeutics

How Advanced Automated Liquid Handling Systems are Reshaping Drug Discovery

How Advanced Automated Liquid Handling Systems are Reshaping Drug Discovery By Helen Stewart-Miller and Dr Richard Massey Winter 2018/19 Once the domain of high-throughput screening (HTS) applications, automated liquid handling systems are now used ubiquitously in drug discovery and have been fundamental in increasing throughput, driving efficiencies and improving standards… Read More

#Archive